CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions

被引:118
|
作者
Nitschke, Lars [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany
关键词
Siglec; B-cell signaling; B-cell differentiation; inhibitory receptors; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MYELIN-ASSOCIATED GLYCOPROTEIN; ALPHA-2,6-LINKED SIALIC ACIDS; HUMANIZED ANTI-CD22 ANTIBODY; HIGH-AFFINITY AUTOANTIBODIES; ADHESION MOLECULE CD22-BETA; N-GLYCOLYLNEURAMINIC ACID; TYROSINE-PHOSPHATASE; 1C; LYN-DEFICIENT MICE; ANTIGEN-RECEPTOR;
D O I
10.1111/j.1600-065X.2009.00801.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Siglecs (sialic acid-binding immunoglobulin-like lectins) are sialic acid-binding proteins, which are expressed on many cell types of the immune system. B cells express two members of the Siglec family, CD22 (Siglec-2) and Siglec-G, both of which have been shown to inhibit B-cell signaling. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha 2-6-linked sialic acids. Interaction with these ligands in cis regulates the association of CD22 with the BCR and thereby modulates the inhibitory function of CD22. Interaction of CD22 to ligands in trans can regulate both B-cell migration as well as the BCR signaling threshold. Siglec-G is a recently identified protein with an inhibitory function restricted to a B-cell subset, the B1 cells. Siglec-G inhibits Ca2+ signaling specifically in these cells. In addition, it controls the cellular expansion and antibody secretion of B1 cells. Thus, both Siglecs modulate BCR signaling on different B-cell populations in a mutually exclusive fashion.
引用
收藏
页码:128 / 143
页数:16
相关论文
共 50 条
  • [41] SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux
    Ostrakhovitch, Elena A.
    Wang, Yefu
    Li, Shawn S-C.
    CELLULAR SIGNALLING, 2009, 21 (04) : 540 - 550
  • [42] Regulation of Human CD27+IgM+B Cell Activation by Cis-Binding of the Inhibitory Molecule CD22 to CD22 Ligand (CD22L)
    Dijke, Esme
    Derkatz, Kim
    Pearcey, Jean
    Wong, Fred
    Motyka, Bruce
    West, Lori
    TRANSPLANTATION, 2017, 101 (05) : S5 - S5
  • [43] Role of CD22/Siglec-2 and its ligand in B lymphocyte activation
    Matsubara, Naoko
    Takematsu, Hiromu
    Ishida, Hideharu
    Tsubata, Takeshi
    GLYCOBIOLOGY, 2014, 24 (11) : 1090 - 1090
  • [44] Investigating the inhibitory function of Siglec-G on B cells using antigenic liposomes decorated with carbohydrate ligands
    Pfrengle, Fabian
    Macauley, Matthew S.
    Paulson, James C.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [45] CD22 IS PART OF THE HUMAN SLGM B-CELL ANTIGEN RECEPTOR SIGNALING COMPLEX
    LEPRINCE, C
    DRAVES, KA
    LEDBETTER, JA
    GEAHLEN, RA
    CLARK, EA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 254 - 254
  • [46] A ROLE IN B-CELL ACTIVATION FOR CD22 AND THE PROTEIN-TYROSINE-PHOSPHATASE SHP
    DOODY, GM
    JUSTEMENT, LB
    DELIBRIAS, CC
    MATTHEWS, RJ
    LIN, JJ
    THOMAS, ML
    FEARON, DT
    SCIENCE, 1995, 269 (5221) : 242 - 244
  • [47] CDNA AND GENOMIC ORGANIZATION OF THE MURINE B-CELL ASSOCIATED ADHESION PROTEIN CD22
    LAW, CL
    TORRES, RM
    KLAUS, SJ
    SUNDBERG, HA
    CLARK, EA
    FASEB JOURNAL, 1992, 6 (04): : A1131 - A1131
  • [48] Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and FcγRII-mediated B cell suppression
    Rudge, EU
    Cutler, AJ
    Pritchard, NR
    Smith, KGC
    JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (08): : 1079 - 1085
  • [49] DEVELOPMENT OF HUMAN B-CELL LINES DEFICIENT IN CD19, CD20, OR CD22
    WILSON, GL
    RIVA, A
    KEHRL, JH
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A99 - A99
  • [50] CDNA CLONING OF THE B-CELL MEMBRANE-PROTEIN CD22 - A MEDIATOR OF B-B-CELL INTERACTIONS
    WILSON, GL
    FOX, CH
    FAUCI, AS
    KEHRL, JH
    JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (01): : 137 - 146